Hematology
Starting from
$47,000
Up to $200,000 depending on centre
Typical duration
20–50 days
Including pre-operative work-up
Partner hospitals
1
Vetted for outcome data & accreditation
Content reviewed for medical accuracy by: Dr. Rodina Ainasoa · Medical Content Writer & Health Communications
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalised cellular immunotherapy in which a patient's own T-cells are genetically engineered to recognise and target specific cancer cells. It is currently FDA-approved for a defined set of relapsed or treatment-resistant blood cancers — including certain B-cell lymphomas, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma — for patients who have already tried standard therapies; response and remission depend on the specific diagnosis and are determined case-by-case by a haematology-oncology specialist. China is a leader in CAR-T manufacturing with domestically approved products (including Relma-cel and Yescarta/Fosun Kite) at a fraction of US prices. India offers the homegrown NexCAR19 product, priced far below imported alternatives, through JCI-accredited centres including Christian Medical College Vellore, though international-patient package costs (covering the full collection-to-monitoring pathway) run higher than the domestic drug price alone.
Your case is matched to a centre on the basis of clinical outcome data, not marketing. We coordinate every step — from pre-operative work-up to post-treatment follow-up — with a dedicated care coordinator.
CAR-T Cell Therapy
Coordinated from
or message us on WhatsApp
No commitment required. Your data is never shared with third parties.
"CAR-T therapy" covers several distinct, individually FDA-approved products that target different proteins for different blood cancers. Here is how the two main product families compare.
| Parameter | CD19-Directed CAR-T | BCMA-Directed CAR-T |
|---|---|---|
| Approved indications | Relapsed or refractory large B-cell lymphoma (including DLBCL), certain other B-cell non-Hodgkin lymphomas, and relapsed or refractory B-cell acute lymphoblastic leukaemia (ALL), generally after standard therapies have failed. | Relapsed or refractory multiple myeloma in patients who have already received several prior lines of therapy. |
| Target antigen | CD19, a protein found on both cancerous and healthy B-cells. | B-cell maturation antigen (BCMA), a protein expressed on plasma cells. |
| FDA-approved product examples | Axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, and lisocabtagene maraleucel, per FDA approvals. | Idecabtagene vicleucel and ciltacabtagene autoleucel, per FDA approvals. |
| Cytokine release syndrome (CRS) | Reported in the large majority of patients in some form, with severe (grade 3 or higher) CRS in roughly 6-10% depending on the specific product, per published clinical trial and real-world data. | Also reported in most patients, though published real-world series report severe (grade 3 or higher) CRS in a smaller proportion, generally under 10%, per ASH-published nationwide analyses. |
| Neurotoxicity (ICANS) | All-grade ICANS reported in roughly 16-33% of patients depending on the product, with severe cases in a smaller subset, per peer-reviewed meta-analyses. | All-grade ICANS generally reported less often than with CD19-directed products, in the range of roughly 10-19% across published series, per peer-reviewed and real-world studies. |
The description below outlines the general process shared across FDA-approved CAR-T products. Your haematology-oncology team will confirm the specific protocol and timeline for your product and diagnosis.
Leukapheresis (T-cell collection)
Blood is drawn and passed through a cell-separator machine that collects white blood cells containing T-cells, with the remaining blood components returned to the patient. The procedure typically takes several hours in an outpatient setting.
Manufacturing and genetic engineering
The collected T-cells are shipped to a specialised manufacturing facility, where they are genetically engineered to express the chimeric antigen receptor, expanded in number, and quality-tested before being shipped back. This process commonly takes about 2 to 4 weeks, though timelines vary by product and manufacturing centre.
Lymphodepleting chemotherapy
In the days immediately before infusion, a short course of chemotherapy (commonly around 3 days) reduces the patient's existing lymphocytes, creating conditions that support expansion of the infused CAR-T cells.
CAR-T cell infusion and early monitoring
The engineered CAR-T cells are infused intravenously, usually in a single visit. Patients are then closely monitored in hospital for early signs of cytokine release syndrome (CRS) or neurotoxicity (ICANS), which most commonly appear within the first one to two weeks after infusion.
The highest-risk window for cytokine release syndrome (CRS) and neurotoxicity (ICANS), both of which typically emerge within this period. Patients remain hospitalised or under close outpatient observation so specialist teams can intervene promptly if symptoms occur.
Many CAR-T recipients are advised to remain within a short distance of the treatment centre for roughly 4 weeks after infusion, given the risk of delayed-onset toxicity, so they can return quickly for evaluation if needed.
Blood counts and immune function gradually recover during this period; low white blood cell and antibody levels can raise infection risk, so patients are monitored for cytopenias and may receive supportive therapies as needed.
Longer-term follow-up continues to track disease response and immune recovery, along with lifelong monitoring for the rare risk of secondary T-cell malignancies, per current FDA guidance for all approved CAR-T products.
Source: FDA; National Cancer Institute; American Society of Hematology-published clinical and real-world studies. Individual recovery varies and is guided by your treating haematology-oncology team.
Known Risks & Limitations
Source: FDA; National Cancer Institute; American Society of Hematology-published nationwide and real-world analyses. No procedure is without risk; your treating haematology-oncology team will review your individual case.
Remote haematology-oncology case review
Share your pathology reports, prior treatment history, imaging, and any molecular or antigen testing already completed. Our coordination team forwards your case for an initial specialist review of whether your specific diagnosis and subtype fall within a current FDA-approved (or other regionally approved) CAR-T indication.
Eligibility confirmation and centre matching
Only a haematology-oncology or cellular therapy specialist can confirm candidacy, based on your cancer subtype, antigen expression, prior lines of therapy, and organ function. Once confirmed, we match you with an accredited CAR-T treatment centre experienced in your specific product and indication.
Cost estimate and travel planning
Because manufacturing and monitoring needs are individualised, a consolidated cost estimate — covering leukapheresis, manufacturing, lymphodepleting chemotherapy, infusion, and inpatient monitoring — is issued only after your case has been reviewed. We also plan for the extended near-centre stay these therapies require.
Treatment and the required ~4-week monitoring period
After leukapheresis and the manufacturing wait, you return for lymphodepleting chemotherapy, infusion, and inpatient monitoring for CRS and ICANS. Most centres require patients to remain within a short distance of the hospital for roughly 4 weeks after infusion because of the risk of delayed-onset complications.
Follow-up and continuity of care
Before you depart, your discharge summary, ongoing monitoring schedule, and specialist contact details are shared with your home-country haematologist-oncologist so they can continue blood-count monitoring, infection-risk management, and long-term follow-up, including the lifelong secondary-malignancy monitoring recommended by the FDA.
Average coordinated costs across our partner centres. Final pricing depends on clinical complexity and chosen hospital.
| Country | Avg. cost | vs. cheapest |
|---|---|---|
🇮🇳 India New Delhi · Chennai · Bengaluru · Hyderabad · Mumbai · Kochi | $65,000 | —chevron_right |
🇨🇳 China Shanghai · Beijing · Hainan (Boao) | $150,000 | +131%chevron_right |
Costs are indicative estimates and vary by procedure specifics, hospital, and clinical complexity. Request a personalised estimate for your specific case.
Faridabad, India
Asia's largest private hospital — 2,600 beds, 64 operation theatres, 81 specialties on a 130-acre campus in Delhi NCR. NABH & NABL accredited. Centres of excellence in oncology, cardiac surgery, BMT, organ transplantation, neurosciences, and IVF.
800+
Specialists
2,600+
Beds
CAR-T is currently approved for relapsed or refractory large B-cell lymphoma (including DLBCL), follicular lymphoma, mantle cell lymphoma, B-cell acute lymphoblastic leukaemia (ALL), and multiple myeloma after prior lines of therapy. Eligibility depends on your specific cancer subtype, prior treatment history, molecular markers (e.g., CD19, BCMA expression), and performance status. Our partner centres will review your pathology reports, treatment history, and imaging to determine candidacy before you travel.
No fees. No commitment.
We are compensated by our partner hospitals — never by patients. You get independent clinical matching, cost transparency, and end-to-end coordination at no cost to you.
